OM
ATXS

Opaleye Management’s Astria Therapeutics ATXS Stock Holding History

Opaleye Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-305,000
Closed -$2.54M – 42
2023
Q2 		$2.54M Buy
305,000
+3,000
+1% +$34.6K 0.61% 35
2023
Q1 		$4.1M Buy
302,000
+40,297
+15% +$545K 1.23% 28
2022
Q4 		$3.9M Buy
261,703
+128,203
+96% +$1.32M 1.36% 23
2022
Q3 		$1.21M Buy
+133,500
New +$895K 0.5% 29
2021
Q1 		– Sell
-31,292
Closed -$402K – 60
2020
Q4 		$402K Buy
+31,292
New +$558K 0.05% 56

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Opaleye Management's ATXS Position: Q3 2023 in Review

Opaleye Management sold out of Astria Therapeutics (ATXS) in Q3 2023, closing a stake of 305,000 shares — an estimated $2.54M sold.

Opaleye Management first reported a position in ATXS in Q4 2020 and held it in 5 quarters. The position peaked at $4.1M in Q1 2023. 68 funds tracked by Wall St. Rank hold ATXS as of Q3 2023.

  • Opaleye Management reported no remaining Astria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Opaleye Management sold 305,000 Astria Therapeutics shares in Q3 2023, an estimated $2.54M.
  • Opaleye Management first reported a position in Astria Therapeutics in Q4 2020 and held it in 5 quarters.
  • Opaleye Management's Astria Therapeutics position peaked at $4.1M in Q1 2023.
  • 68 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.